Why this scaffold works across so many joints

The short answer is yes — ChondroFiller® is not a knee-only treatment. Published clinical use covers large joints (knee, hip, shoulder, and ankle) and small joints including the thumb, fingers, elbow, AC joint, wrist, foot, toes, and the temporomandibular joint (TMJ).

The reason the scaffold travels so readily across the joint map comes down to chemistry rather than anatomy. ChondroFiller® is a cell-free, type I collagen hydrogel: there are no cartilage cells in the vial. Once the gel is placed into a prepared defect under ultrasound guidance as an outpatient injection, it self-sets within roughly three to five minutes and forms a stable matrix. The patient's own cells then migrate in and use that matrix as a framework for the body's natural repair process. Because the gel relies on host-cell infiltration rather than a pre-loaded cell population, the underlying biology works in a small wrist joint the same way it works in a hip or a shoulder. What changes between joints is the delivery technique — needle angle, volume, approach — not the scaffold's chemistry.

What does constrain eligibility is not which joint is involved but how the damage is distributed within it. Defect morphology — whether the lesion is focal and contained or diffuse — matters more than joint identity, and that question is covered in detail when assessing individual suitability.

Hip cartilage defects: the strongest evidence outside the knee

Among all joints treated beyond the knee, the hip has accumulated the most substantial published evidence base. A prospective cohort study following 26 patients — all with focal full-thickness acetabular lesions larger than 2 cm², often arising after femoroacetabular impingement — reported that 17 of 21 evaluable patients achieved good or excellent results at three to five years, assessed on both MRI imaging and clinical scoring. Published series indicate improvements in Harris Hip Score in the region of 33 points. For patients, that kind of shift typically translates to meaningful reductions in groin or deep hip pain at rest and on walking, and an improved ability to manage daily activities without the low-grade constant ache that focal cartilage damage can cause. MOCART scores — a standardised MRI measure of how well the treated area integrates and matures — have been reported in the 70–87 range across treated hips, suggesting durable scaffold incorporation at medium-term follow-up.

The most important eligibility filter for the hip is the degree of wear already visible on imaging before treatment. Patients whose imaging reveals significant pre-existing joint-space narrowing — what orthopaedic assessments describe as Tönnis grade 2 or 3 osteoarthritis — have consistently shown poor outcomes in published hip series, and this level of generalised degeneration is considered a firm contraindication. The scaffold is designed for focal, contained lesions in an otherwise preserved joint, not to address diffuse cartilage loss. Patients with isolated post-impingement or post-traumatic chondral defects, in a joint that retains reasonable overall architecture, represent the group where published evidence is most encouraging.

Wrist and small joint applications

Published peer-reviewed evidence for small-joint use centres on a 2025 prospective study examining ChondroFiller® in 25 patients who had sustained intra-articular distal radius fractures — injuries that commonly damage the cartilage lining the wrist joint at the same time as the bone. Compared with a control group, patients who received the collagen scaffold showed significantly better cartilage quality at follow-up arthroscopy: median Outerbridge scores of 1.5 versus 3, and ICRS grades of 1 versus 3 (P=0.006 and P=0.002 respectively). In practical terms, a score of 1 on both scales indicates near-normal cartilage surface, while a score of 3 describes deep, fragmented damage — so the treated group's cartilage quality was rated substantially better on direct inspection than the untreated group, a difference that reached clear statistical significance.

One feature of the wrist study that has practical relevance for any small-joint application is the volume required. Only 0.2–0.3 mL of the 1 mL vial was needed per defect, which means a single vial can cover several small lesions in the same sitting — a meaningful consideration for patients with cartilage damage affecting multiple fingers or toes.

For hand and finger joints, including the thumb basal (CMC-1) joint, clinical practice data suggest that ChondroFiller® use has been described with reported reductions in pain and improvements in grip strength, alongside MRI signals indicating increased joint space. Independent controlled trial data specific to these joints are not yet available, and outcomes should be understood in that context.

Small-joint delivery differs from large-joint technique in one important practical respect: the injection must be placed with a fine-gauge needle under ultrasound guidance to reach the target accurately within a confined space. The scaffold's rapid self-gelling property — setting within a few minutes of placement — prevents dispersal once delivered, which matters when working with smaller joint volumes.

Beyond the wrist, documented small-joint applications include the elbow, AC joint (between the collarbone and shoulder blade), toes, and the temporomandibular joint. Patients concerned about cartilage damage in any of these areas would need an individual assessment to determine whether a focal, contained defect is present and whether the approach is appropriate for their specific joint.

Shoulder and ankle: where evidence is still developing

Ankle and shoulder represent two joints where ChondroFiller® is used in clinical practice, though the published evidence base sits at an earlier stage than the hip data.

Ankle. The primary target is the osteochondral lesion of the talus (OLT) — a focal area of cartilage and bone damage that frequently follows ankle sprains or fractures and can cause persistent deep ankle pain long after the original injury has apparently healed. OLTs are typically well-contained focal defects rather than diffuse joint-wide wear, which suits the scaffold's design: the gel fills the crater, sets in place under ultrasound guidance, and provides a stable environment for local cell ingrowth. Clinical practice descriptions support this application; dedicated published cohort studies comparable in scope to the hip series are not yet available.

Shoulder. Here the scaffold is directed at focal chondral lesions on the humeral head or glenoid surface — defects that tend to arise after trauma, dislocation, or instability rather than from diffuse glenohumeral osteoarthritis. The same evidence caveat applies: clinical practice guidance supports its use, but dedicated outcome series for shoulder-specific cohorts have not yet appeared in peer-reviewed literature.

Confidence in both applications rests on the scaffold's consistent biological behaviour across joint types. A 2025 ex vivo study confirmed a 2.4-fold increase in cell recruitment by day 14, irrespective of joint context — which is why clinical application has preceded large-scale site-specific trial data. For a patient with a focal shoulder or ankle defect, the practical question at consultation is whether the defect morphology — containment, depth, and the overall state of the surrounding joint — makes it a suitable target, and whether the published hip and wrist findings serve as a reasonable proxy for what the scaffold may achieve in their case.

ChondroFiller injection vs Liquid Cartilage™: two different pathways

Patients searching for information on 'Liquid Cartilage™' sometimes arrive expecting to read about the same outpatient injection described in the sections above. The two terms describe different clinical pathways, and spelling out that difference is the most useful thing this section can do.

The ChondroFiller® injection is the outpatient route: the collagen gel scaffold is placed under ultrasound guidance in a clinic setting, with no fixed upper limit on the size of a focal defect eligible for treatment — though the patient still requires a contained, focal lesion rather than diffuse joint-wide cartilage loss. This is the pathway covered throughout this article, and it applies across the full range of large and small joints discussed above.

Liquid Cartilage™ is a more involved clinical pathway, planned and delivered differently. It combines the same collagen scaffold with a cell-delivery technique applied directly to an excavated focal defect, making it more dependent on the patient's own regenerative capacity and reserved for specific defect profiles where that approach is indicated. The two are not interchangeable names for the same treatment.

Which pathway — if either — is appropriate depends on the defect's size, location, depth, and the overall state of the surrounding joint. A specialist assessment is the only reliable way to determine that.

What makes someone a suitable candidate across joints

The most useful question at this stage is not 'which joint?' but 'is my particular joint situation suitable?' The answer rests on factors that go beyond anatomy — and several cannot be assessed without specialist imaging.

Imaging comes first. A plain X-ray shows bone and joint space but cannot map the depth, containment, or defined edges of a cartilage defect. An MRI is required before any treatment plan can be formed across any of the joints covered in this article. It is the only reliable way to confirm that a lesion is truly focal and bounded — not spread across multiple compartments — and to rule out underlying bone pathology that would change the clinical picture entirely.

Bodyweight and joint load. In load-bearing joints such as the hip and ankle, the mechanical force acting on a scaffold during early healing is part of the suitability calculation. This is assessed individually alongside the defect's size and location; there is no single weight threshold that applies across all joints or all defect profiles.

Systemic health and medication. Conditions or drugs that impair tissue repair — certain immunosuppressants, for example — are reviewed as part of pre-treatment assessment. Again, no blanket rule applies; the relevance depends on the joint, the pathway being considered, and the patient's overall health picture.

Activity goals matter as much as imaging. A patient aiming to return to recreational sport has a different risk-benefit profile from one seeking relief from everyday pain. Suitability is not a binary checklist; it is a clinical judgement that weighs imaging findings, joint load, general health, and what the patient is trying to achieve. A specialist assessment — with MRI to hand — is the only route to that judgement.

1. [1] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
2. [2] Arthroscopic utilization of ChondroFiller gel for treatment of hip articular cartilage defects: cohort study with 12–60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
3. [3] Randomized multicenter study: ChondroFiller liquid vs microfracturing for focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
4. [4] Ex Vivo Osteochondral Biomimetic Platform for Cartilage Regeneration (ChondroFiller®). (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759